Sandra E. Kurtin, PhDc, ANP-C, AOCN, on Treatment of CLL/SLL: 7-Year Follow-up Data

Sandra E. Kurtin, PhDc, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses phase Ib/II study findings on single-agent ibrutinib in the first-line and relapsed or refractory settings for chronic lymphocytic leukemia/small lymphocytic lymphoma (Abstract 3133).